Trabectedin and Campthotecin Synergistically Eliminate Cancer Stem Cells in Cell-of-Origin Sarcoma Models()

Trabectedin has been approved for second-line treatment of soft tissue sarcomas. However, its efficacy to target sarcoma initiating cells has not been addressed yet. Here, we used pioneer models of myxoid/round cell liposarcoma (MRCLS) and undifferentiated pleomorphic sarcoma (UPS) developed from tr...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Neoplasia
Autors principals: Martinez-Cruzado, Lucia, Tornin, Juan, Rodriguez, Aida, Santos, Laura, Allonca, Eva, Fernandez-Garcia, Maria Teresa, Astudillo, Aurora, Garcia-Pedrero, Juana Maria, Rodriguez, Rene
Format: Artigo
Idioma:Inglês
Publicat: Neoplasia Press 2017
Matèries:
Original article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5421973/
https://ncbi.nlm.nih.gov/pubmed/28494349
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.neo.2017.03.004
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars